CHMP recommends Novo Nordisk's Saxenda for adolescents
The EU Committee for Medicinal Products for Human Use (CHMP) which recommends drugs for approval in Europe, vouches for an expanded indication of Novo Nordisk's obesity drug Saxenda, so it can be used for adolescents aged 12-17 years.
BY RITZAU, TRANSLATED BY NIELSINE NIELSEN
European health authorities recommend an extended use of Novo Nordisk's weight loss drug Saxenda so that it may also be used for treating obesity in children and adolescents aged 12-17, according to a Novo Nordisk press release.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.